LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
Morten Nielsen(Copenhagen University Hospital), Inge Marie Svane(Copenhagen University Hospital), Ketil André Camilio(Oslo University Hospital), Vibeke Sundvold(Lytix Biopharma (Norway)), Benedetta Albieri(Copenhagen University Hospital), Tine Monberg(Herlev Hospital), Anders Krarup‐Hansen(Herlev Hospital), Baldur Sveinbjørnsson(Lytix Biopharma (Norway)), Özcan Met(Herlev Hospital), Michael Mørk Petersen(Copenhagen University Hospital), Trevor Clancy(Inholland University of Applied Sciences), Richard Stratford, Øystein Rekdal(Lytix Biopharma (Norway)), Dorrit Hovgaard(Copenhagen University Hospital), Niels Junker(Gentofte Hospital)
Cited by 40
Related Papers
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
|The Lancet Oncology|2014|1.2k
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345